氧化低密度脂蛋白与年龄相关性黄斑变性发病的关系
该研究基于Beaver Dam眼研究(BDES)25年随访数据,纳入4972名43-84岁参与者,对其中2468人随机抽样检测血清ox-LDL,采用多状态马尔可夫模型分析ox-LDL与AMD发病及进展的关系。结果显示,调整年龄、性别、ARMS2和CFH风险等位基因及检查阶段后,ox-LDL与任何AMD发病、晚期AMD发病及AMD严重程度恶化均无统计学显著关联。
要点
- ox-LDL每升高10 U/L,任何AMD发病的风险比为1.03(95%CI 0.98-1.09),无统计学显著性。
- ox-LDL与AMD严重程度量表上的恶化及晚期AMD发病均无显著关联。
- 调整他汀使用、吸烟、BMI和心血管病史后,上述无关联的结果保持不变。
核心结论
- 本研究未提供ox-LDL与AMD发病或恶化存在统计学显著关系的证据。
研究设计与样本
- 观察性前瞻性队列研究,基于Beaver Dam眼研究(BDES)人群。
- 共4972名43-84岁参与者,在1988至2016年间约每5年一次的6个检查阶段中至少参加1次。
- 随机抽取50%样本(N=2468)进行ox-LDL检测,使用单批次酶联免疫吸附 assay 处理各检查阶段冻存标本,共纳入6586人次访视。
- AMD采用Wisconsin年龄相关性黄斑病变分级系统评估,严重程度采用5级量表,取每次检查中较差眼的严重程度进行分析。
- 采用多状态马尔可夫(MSM)模型同时评估ox-LDL与任何AMD发病、晚期AMD发病及AMD恶化与改善的关系。
主要发现
- 基线检查时ox-LDL平均(标准差)水平为75.3(23.1)U/L。
- 调整年龄、性别、ARMS2和CFH风险等位基因及检查阶段后,ox-LDL与任何AMD发病无统计学显著关联(每10 U/L的风险比为1.03,95%CI 0.98-1.09)。
- ox-LDL与AMD严重程度量表上的任何恶化及晚期AMD发病均无关联。
- 调整他汀使用史、吸烟状态、体重指数和心血管疾病史后,ox-LDL与任何AMD发病或AMD恶化的无关联结果保持不变(数据未展示)。
临床怎么用
- 血清ox-LDL水平不宜作为评估AMD发病或进展风险的独立生物标志物。
- 在AMD风险咨询中,不应基于ox-LDL检测结果调整筛查或干预策略。
局限性
- 原文未报告局限性相关内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To examine the relationship between serum oxidized low-density lipoprotein (ox-LDL) cholesterol and the incidence of age-related macular degeneration (AMD) over a 25-year period in a sample of persons from the population-based Beaver Dam Eye Study (BDES). DESIGN: Observational prospective cohort study. PARTICIPANTS: A total of 4972 people from the BDES (aged 43-84 years and living in Beaver Dam, Wisconsin in 1988) seen during at least 1 of 6 examination phases at approximately 5-year intervals between 1988 and 2016. METHODS: A 50% random sample of participants (N = 2468) was selected for ox-LDL measurements. Stored frozen specimens from every examination phase were processed using an enzyme-linked immunosorbent assay from a single batch. All available intervals were included for a person, resulting in 6586 person-visits. MAIN OUTCOME MEASURES: Age-related macular degeneration was assessed using the Wisconsin Age-related Maculopathy Grading System, and severity was defined using a 5-step severity scale. The severity of the worse eye at each examination was used for analyses. A multi-state Markov (MSM) model was fit to simultaneously assess the ox-LDL relationship to all AMD transitions, including incidence of any AMD, incidence of late AMD, and worsening and improvement of AMD over the 25 years of the study. RESULTS: The mean (standard deviation) level of ox-LDL was 75.3 (23.1) U/L at the baseline examination. When adjusting for age, sex, ARMS2 and CFH risk alleles, and examination phase, the ox-LDL at the beginning of a period was not statistically significantly associated with the incidence of any AMD (hazard ratio per 10 U/L ox-LDL was 1.03, 95% confidence interval 0.98,1.09). Furthermore, ox-LDL was not associated with worsening anywhere along the AMD severity scale, nor with incidence of late AMD. The lack of relationships of ox-LDL to the incidence of any AMD or worsening of AMD remained after adjustment for history of statin use, smoking status, body mass index, and history of cardiovascular disease (data not shown). CONCLUSIONS: Our findings do not provide evidence for statistically significant relationships between ox-LDL and AMD disease development or worsening of AMD.
引用
- Klein R, Lee KE, Tsai MY, et al. Oxidized Low-density Lipoprotein and the Incidence of Age-related Macular Degeneration. Ophthalmology. 2018. PMID: 30572074. doi:10.1016/j.ophtha.2018.12.026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。